The time is now: Achieving FH paediatric screening across Europe – The Prague Declaration
- Nicole Bedlington 1
- Marianne Abifadel 353637
- Birgit Beger 21
- Mafalda Bourbon 2223
- Héctor Bueno 1516171819
- Richard Ceska 42
- Kristýna Cillíková 2
- Zdenka Cimická 2
- Magdalena Daccord 1
- Carine de Beaufort 20
- Kanika I. Dharmayat 7
- Brian A. Ference 32
- Tomáš Freiberger 4344
- Marius Geanta 1
- Samuel S. Gidding 1
- Urh Grošelj 2728
- Martin Halle 34
- Neil Johnson 13
- Tanja Novakovic 5
- Ondrej Májek 3839
- Athanasios Pallidis 6
- Noel Peretti 1011
- Fausto J. Pinto 2526
- Kausik Kosh Ray 78
- Bleddyn Rees 3334
- John Reeve 1
- Željko Reiner 41
- Raul D. Santos 293031
- Heribert Schunkert 12
- Jaka Šikonja 27
- Milka Sokolovic 24
- Lale Tokgözoglu 89
- Michal Vrablík 4546
- Albert Wiegman 40
- Iñaki Gutiérrez-Ibarluzea 14
- Alle Autoren anzeigen +
- 1 FH Europe, Star House, Rochester, UK
- 2 Diagnoza FH, Libáň, Czech Rep
- 3 Department of Prevention & Sports Medicine, University Hospital Klinikum rechts der Isar, Technical University of Munich, Munich, Germany
- 4 Deutsches Zentrum für Herz-Kreislauf-Forschung, Munich Heart Alliance, Munich, Germany
- 5 ZEM Solutions Ltd, Belgrade, Serbia
- 6 LDL Greece, Athens, Greece
- 7 Imperial Centre for Cardiovascular Disease Prevention, Department of Primary Care and Public Health, Imperial College London, London, UK
- 8 European Atherosclerosis Society, Göteborg, Sweden
- 9 Department of Cardiology, Hacettepe University, Ankara, Turkey
- 10 Department of Pediatric Gastroenterology-Hepatology & Nutrition, Hospices Civil de Lyon HCL, Hôpital Femme Mere Enfant HFME, Bron, France
- 11 Univ-Lyon, CarMeN laboratory, INSERM U1060, INRAE U1397, Université Claude Bernard Lyon-1, Oullins, Lyon, France
- 12 Deutsches Herzzentrum München, Munich, Germany
- 13 Global Heart Hub, Galway, Ireland
- 14 Basque Foundation for Health Innovation and Research, Barakaldo, Spain
- 15 Centro Nacional de Investigaciones Cardiovasculares, Madrid, Spain
- 16 Cardiology Department, Hospital Universitario 12 de Octubre, Madrid, Spain
- 17 Instituto de Investigación Sanitaria Hospital 12 de Octubre (imas12), Madrid, Spain
- 18 Centro de Investigación Biomédica en Red Enfermedades Cardiovaculares, Madrid, Spain
- 19 Facultad de Medicina, Universidad Complutense de Madrid, Madrid, Spain
- 20 Diabetes & Endocrine Care Clinique Pediatrique/CHL, Luxembourg, Grand Duchy Luxembourg
- 21 European Heart Network, European Alliance for Cardiovascular Health, Brussels, Belgium
- 22 Unidade de I&D, Grupo de Investigação Cardiovascular, Departamento de Promoção da Saúde e Prevenção de Doenças Não Transmissíveis, Instituto Nacional de Saúde Doutor Ricardo Jorge, Lisboa, Portugal
- 23 BioISI – Biosystems & Integrative Sciences Institute, Faculdade de Ciências, Universidade de Lisboa, Lisboa, Portugal
- 24 Europan Public Health Alliance, Brussels, Belgium
- 25 World Heart Federation, Geneva, Switzerland
- 26 Cardiovascular Department, CCUL, CAML, Lisbon School of Medicine, University of Lisbon, Lisbon, Portugal
- 27 Department of Endocrinology, Diabetes & Metabolic Diseases, University Children’s Hospital, University Medical Centre Ljubljana, Ljubljana, Slovenia
- 28 Faculty of Medicine, University of Ljubljana, Ljubljana, Slovenia
- 29 Lipid Clinic Heart Institute, University of Sao Paulo Medical School Hospital, Sao Paulo, Brazil
- 30 Hospital Israelita Albert Einstein, Sao Paulo, Brazil
- 31 International Atherosclerosis Society, Milan, Italy
- 32 University Of Cambridge, Clinical School, Cambridge, UK
- 33 The Digital Health Society, Dublin, Ireland
- 34 The European Connected Health Alliance, Belfast, UK
- 35 Laboratory of Biochemistry & Molecular Therapeutics, Faculty of Pharmacy, Pôle Technologie–Santé, Saint Joseph University of Beirut, Beirut, Lebanon
- 36 Laboratory for Vascular Translational Science, Paris Cité University, Paris, France
- 37 Sorbonne Paris Nord University, INSERM, Paris, France
- 38 National Screening Centre, Institute of Health Information & Statistics of the Czech Republic, Prague, Czech Rep
- 39 Institute of Biostatistics & Analyses, Faculty of Medicine, Masaryk University, Brno, Czech Rep
- 40 University of Amsterdam, Department of Paediatrics, Amsterdam, Netherlands
- 41 University Hospital Center Zagreb, Department for Metabolic Diseases, Zagreb, Croatia
- 42 3rd Department of Medicine – Department of Endocrinology & Metabolism of the 1st Faculty of Medicine, Charles University & General University Hospital, Prague, Czech Rep
- 43 Centre for Cardiovascular Surgery and Transplantation, Brno, Czech Rep
- 44 Medical Faculty, Masaryk University, Brno, Czech Rep
- 45 3rd Department of Internal Medicine, General Teaching Hospital, Prague, Czech Rep
- 46 1st Faculty of Medicine, Charles University, Prague, Czech Rep
Datum der Publikation: 2022
Ausgabe: 16
Art: Artikel
Zusammenfassung
Familial hypercholesterolaemia (FH) is the most common inherited metabolic disorder characterized by high cholesterol and if left untreated leads to premature cardiovascular disease, such as heart attacks. Treatment that begins early in life, particularly in childhood, is highly efficacious in preventing cardiovascular disease and cost-effective, thus early detection of FH is crucial. However, in Europe, less than 10% of people living with FH are diagnosed and even less receive life-saving treatment. The Prague Declaration is a call to action for national and European Union policymakers and decision-makers and a result of the Czech EU Presidency meeting on FH Paediatric Screening (early detection of inherited high cholesterol) at the Czech Senate in Prague on 6th September 2022. It builds on a considerable body of evidence which was discussed at the Technical Meeting under the auspices of the Slovenian EU Presidency in October 2021. The Prague meeting addressed the outstanding barriers to the systematic implementation of FH paediatric screening across Europe. In this article, we present the key points from the Prague meeting and concrete actions needed to move forward.